{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:18:56Z","timestamp":1783124336438,"version":"3.54.6"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Multiple myeloma (MM) is the second most prevalent hematological malignancy that results in the proliferation of malignant plasma cells and the overproduction of monoclonal immunoglobulin. Visfatin plays an important role in the regulation of apoptosis, oxidative stress, and inflammation; however, to this date, the role of visfatin in multiple myeloma is unclear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To explore the role of visfatin in multiple myeloma and find new targets for MM treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this study, expression of visfatin in bone marrow was detected by ELISA. The diagnostic value of visfatin was determined by receiver operating characteristic (ROC) curve analysis. After the quality control by performing western blot to confirm the knockdown of visfatin in two MM cell lines, the phenotype (proliferation and apoptosis) of visfatin in MM was determined by carrying out in vitro experiments, including CCK8, flow cytometry, and western blot. Several cytokines were determined by real-time PCR, followed by in vivo experiments and immunohistochemical assays. I\u03baB, NF-\u03babp65, and phosphorylation were determined by western blot.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We found that visfatin level increased in the bone marrow of MM patients compared to controls. ROC curve analysis result showed that bone marrow visfatin was able to distinguish MM patients from controls. In vitro and in vivo, visfatin promotes MM cell proliferation. The production of IL-6 was attenuated by visfatin knockdown. Furthermore, we showed that visfatin could activate IL-6 production via the NF-\u03baB signaling pathway.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In MM, visfatin promotes tumor progression by upregulating IL-6 production, which may be a novel therapeutic target for the treatment of MM patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12672-025-02682-1","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T13:16:50Z","timestamp":1747747010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Visfatin promotes multiple myeloma cell proliferation and inhibits apoptosis by inducing IL-6 production via NF-\u03baB pathways"],"prefix":"10.1007","volume":"16","author":[{"given":"Wenting","family":"Tie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"2682_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet (London, England). 2021;397:410\u201327.","journal-title":"Lancet (London, England)"},{"key":"2682_CR2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4:1221\u20137.","journal-title":"JAMA Oncol"},{"key":"2682_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10:45.","journal-title":"Nat Rev Dis Primers"},{"key":"2682_CR4","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"2682_CR5","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.3390\/ijms25116192","volume":"25","author":"CH-T Lin","year":"2024","unstructured":"Lin CH-T, Tariq MJ, Ullah F, Sannareddy A, Khalid F, Abbas H, et al. Current novel targeted therapeutic strategies in multiple myeloma. Int J Mol Sci. 2024;25:6192.","journal-title":"Int J Mol Sci"},{"key":"2682_CR6","doi-asserted-by":"publisher","first-page":"1611338","DOI":"10.3389\/pore.2023.1611338","volume":"29","author":"W Tie","year":"2023","unstructured":"Tie W, Ma T, Yi Z, Liu J, Li Y, Bai J, et al. Obesity as a risk factor for multiple myeloma: insight on the role of adipokines. Pathol Oncol Res. 2023;29:1611338.","journal-title":"Pathol Oncol Res"},{"key":"2682_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41574-023-00893-6","volume":"19","author":"I AlZaim","year":"2023","unstructured":"AlZaim I, de Rooij LPMH, Sheikh BN, B\u00f6rgeson E, Kalucka J. The evolving functions of the vasculature in regulating adipose tissue biology in health and obesity. Nat Rev Endocrinol. 2023;19:691.","journal-title":"Nat Rev Endocrinol"},{"key":"2682_CR8","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1177\/1753425912439614","volume":"18","author":"E Schilling","year":"2012","unstructured":"Schilling E, Hauschildt S. Extracellular ATP induces P2X7-dependent nicotinamide phosphoribosyltransferase release in LPS-activated human monocytes. Innate Immun. 2012;18:738\u201344.","journal-title":"Innate Immun"},{"key":"2682_CR9","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/jcbfm.2014.119","volume":"34","author":"Z Jing","year":"2014","unstructured":"Jing Z, Xing J, Chen X, Stetler RA, Weng Z, Gan Y, et al. Neuronal NAMPT is released after cerebral ischemia and protects against white matter injury. J Cereb Blood Flow Metab. 2014;34:1613\u201321.","journal-title":"J Cereb Blood Flow Metab"},{"key":"2682_CR10","doi-asserted-by":"publisher","first-page":"34189","DOI":"10.1074\/jbc.M114.594721","volume":"289","author":"D Soncini","year":"2014","unstructured":"Soncini D, Caffa I, Zoppoli G, Cea M, Cagnetta A, Passalacqua M, et al. Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. J Biol Chem. 2014;289:34189\u2013204.","journal-title":"J Biol Chem"},{"key":"2682_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood-2014-07-589069","volume":"125","author":"V Audrito","year":"2015","unstructured":"Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, et al. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood. 2015;125:111\u201323.","journal-title":"Blood"},{"key":"2682_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120706","volume":"304","author":"PK Rajput","year":"2022","unstructured":"Rajput PK, Sharma JR, Yadav UCS. Cellular and molecular insights into the roles of visfatin in breast cancer cells plasticity programs. Life Sci. 2022;304: 120706.","journal-title":"Life Sci"},{"key":"2682_CR13","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.3390\/cancers14092059","volume":"14","author":"T-C Lin","year":"2022","unstructured":"Lin T-C. Updated functional roles of NAMPT in carcinogenesis and therapeutic niches. Cancers (Basel). 2022;14:2059.","journal-title":"Cancers (Basel)."},{"key":"2682_CR14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.exphem.2013.02.008","volume":"41","author":"SU Venkateshaiah","year":"2013","unstructured":"Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, et al. NAMPT\/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. Exp Hematol. 2013;41:547.","journal-title":"Exp Hematol"},{"key":"2682_CR15","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1038\/s41375-019-0470-4","volume":"33","author":"AK Mishra","year":"2019","unstructured":"Mishra AK, Dingli D. Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. Leukemia. 2019;33:2695\u2013709.","journal-title":"Leukemia"},{"key":"2682_CR16","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1038\/leu.2015.145","volume":"29","author":"T Matthes","year":"2015","unstructured":"Matthes T, Manfroi B, Zeller A, Dunand-Sauthier I, Bogen B, Huard B. Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow. Leukemia. 2015;29:1882\u201390.","journal-title":"Leukemia"},{"key":"2682_CR17","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1038\/sj.onc.1206423","volume":"22","author":"M Jourdan","year":"2003","unstructured":"Jourdan M, Veyrune J-L, De Vos J, Redal N, Couderc G, Klein B. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene. 2003;22:2950\u20139.","journal-title":"Oncogene"},{"key":"2682_CR18","doi-asserted-by":"publisher","first-page":"27845","DOI":"10.1074\/jbc.M003428200","volume":"275","author":"D Chauhan","year":"2000","unstructured":"Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies FE, et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem. 2000;275:27845\u201350.","journal-title":"J Biol Chem"},{"key":"2682_CR19","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","volume":"18","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson L, Baljevic M, Campagnaro E, et al. Multiple myeloma, Version 3.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:1685\u2013717.","journal-title":"J Natl Compr Canc Netw"},{"key":"2682_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102684","volume":"298","author":"B Wang","year":"2022","unstructured":"Wang B, Zhao Q, Gong X, Wang C, Bai Y, Wang H, et al. Transmembrane anterior posterior transformation 1 regulates BMP signaling and modulates the protein stability of SMAD1\/5. J Biol Chem. 2022;298: 102684.","journal-title":"J Biol Chem"},{"key":"2682_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110474","volume":"100","author":"T Ma","year":"2022","unstructured":"Ma T, Chen Y, Yi Z-G, Liu J, Li Y-H, Bai J, et al. NORAD promotes multiple myeloma cell progression via BMP6\/P-ERK1\/2 axis. Cell Signal. 2022;100: 110474.","journal-title":"Cell Signal"},{"key":"2682_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2024.135105","volume":"477","author":"H-Y Huang","year":"2024","unstructured":"Huang H-Y, Chen C-H, Cheng F-J, Wang B-W, Tu C-Y, Chen Y-J, et al. Incense-burning smoke ingredient auramine enhances lincRNA-p21 expression for chemosensitization in p53-mutated non-small cell lung cancer. J Hazard Mater. 2024;477: 135105.","journal-title":"J Hazard Mater"},{"key":"2682_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105584","volume":"213","author":"N Lin","year":"2023","unstructured":"Lin N, Wang L, Guo Z, Guo S, Liu C, Lin J, et al. miR-548c-3p targets TRIM22 to attenuate the Peg-IFN-\u03b1 therapeutic efficacy in HBeAg-positive patients with chronic hepatitis B. Antiviral Res. 2023;213: 105584.","journal-title":"Antiviral Res"},{"key":"2682_CR24","unstructured":"Guidelines for Endpoints in Animal Study Proposals. National Institutes of Health (NIH); 2019."},{"key":"2682_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110814","volume":"110","author":"Z Yi","year":"2023","unstructured":"Yi Z, Ma T, Liu J, Tie W, Li Y, Bai J, et al. LGR4 promotes tumorigenesis by activating TGF-\u03b21\/Smad signaling pathway in multiple myeloma. Cell Signal. 2023;110: 110814.","journal-title":"Cell Signal"},{"key":"2682_CR26","doi-asserted-by":"publisher","first-page":"1102471","DOI":"10.3389\/fimmu.2022.1102471","volume":"13","author":"C Giannotta","year":"2022","unstructured":"Giannotta C, Autino F, Massaia M. The immune suppressive tumor microenvironment in multiple myeloma: the contribution of myeloid-derived suppressor cells. Front Immunol. 2022;13:1102471.","journal-title":"Front Immunol"},{"key":"2682_CR27","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/cells8080874","volume":"8","author":"S Cheleschi","year":"2019","unstructured":"Cheleschi S, Tenti S, Mondanelli N, Corallo C, Barbarino M, Giannotti S, et al. MicroRNA-34a and MicroRNA-181a mediate visfatin-induced apoptosis and oxidative stress via NF-\u03baB pathway in human osteoarthritic chondrocytes. Cells. 2019;8:874.","journal-title":"Cells"},{"key":"2682_CR28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3892\/ijmm.2017.3048","volume":"40","author":"L Sun","year":"2017","unstructured":"Sun L, Chen S, Gao H, Ren L, Song G. Visfatin induces the apoptosis of endothelial progenitor cells via the induction of pro-inflammatory mediators through the NF-\u03baB pathway. Int J Mol Med. 2017;40:637\u201346.","journal-title":"Int J Mol Med"},{"key":"2682_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2021.119042","volume":"1868","author":"S Yao","year":"2021","unstructured":"Yao S, Jiang C, Zhang H, Gao X, Guo Y, Cao Z. Visfatin regulates Pg LPS-induced proinflammatory\/prodegradative effects in healthy and inflammatory periodontal cells partially via NF-\u03baB pathway. Biochim Biophys Acta Mol Cell Res. 2021;1868: 119042.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"2682_CR30","first-page":"1112","volume":"45","author":"Z Liu","year":"2020","unstructured":"Liu Z, Liu H, Li Y, Wang Y, Xing R, Mi F, et al. Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma. Int J Mol Med. 2020;45:1112\u201320.","journal-title":"Int J Mol Med"},{"key":"2682_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.peptides.2017.04.007","volume":"92","author":"Z Gholinejad","year":"2017","unstructured":"Gholinejad Z, Kheiripour N, Nourbakhsh M, Ilbeigi D, Behroozfar K, Hesari Z, et al. Extracellular NAMPT\/Visfatin induces proliferation through ERK1\/2 and AKT and inhibits apoptosis in breast cancer cells. Peptides. 2017;92:9.","journal-title":"Peptides"},{"key":"2682_CR32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ygyno.2016.07.109","volume":"143","author":"Y Wang","year":"2016","unstructured":"Wang Y, Gao C, Zhang Y, Gao J, Teng F, Tian W, et al. Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K\/Akt and MAPK\/ERK1\/2 signalling pathways. Gynecol Oncol. 2016;143:168\u201378.","journal-title":"Gynecol Oncol"},{"key":"2682_CR33","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1158\/1535-7163.MCT-16-0197","volume":"15","author":"O Abu Aboud","year":"2016","unstructured":"Abu Aboud O, Chen C-H, Senapedis W, Baloglu E, Argueta C, Weiss RH. Dual and specific inhibition of NAMPT and PAK4 By KPT-9274 decreases kidney cancer growth. Mol Cancer Ther. 2016;15:2119\u201329.","journal-title":"Mol Cancer Ther"},{"key":"2682_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1006\/cyto.2001.0982","volume":"16","author":"VM Lauta","year":"2001","unstructured":"Lauta VM. Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data. Cytokine. 2001;16:79\u201386.","journal-title":"Cytokine"},{"key":"2682_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12974-023-02754-5","volume":"20","author":"Y Shi","year":"2023","unstructured":"Shi Y, Liu Y, Wu C, Liu X, Hu W, Yang Z, et al. N,N-Dimethyl-3\u03b2-hydroxycholenamide attenuates neuronal death and retinal inflammation in retinal ischemia\/reperfusion injury by inhibiting Ninjurin 1. J Neuroinflammation. 2023;20:91.","journal-title":"J Neuroinflammation"},{"key":"2682_CR36","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1158\/1535-7163.MCT-17-0786","volume":"17","author":"S Inoue","year":"2018","unstructured":"Inoue S, Ide H, Mizushima T, Jiang G, Netto GJ, Gotoh M, et al. Nuclear factor-\u03baB promotes urothelial tumorigenesis and cancer progression via cooperation with androgen receptor signaling. Mol Cancer Ther. 2018;17:1303\u201314.","journal-title":"Mol Cancer Ther"},{"key":"2682_CR37","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ajpath.2013.01.044","volume":"182","author":"CS Hau","year":"2013","unstructured":"Hau CS, Kanda N, Noda S, Tatsuta A, Kamata M, Shibata S, et al. Visfatin enhances the production of cathelicidin antimicrobial peptide, human \u03b2-defensin-2, human \u03b2-defensin-3, and S100A7 in human keratinocytes and their orthologs in murine imiquimod-induced psoriatic skin. Am J Pathol. 2013;182:1705\u201317.","journal-title":"Am J Pathol"},{"key":"2682_CR38","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bcpt.12623","volume":"119","author":"G Wang","year":"2016","unstructured":"Wang G, Tian W, Liu Y, Ju Y, Shen Y, Zhao S, et al. Visfatin triggers the cell motility of non-small cell lung cancer via up-regulation of matrix metalloproteinases. Basic Clin Pharmacol Toxicol. 2016;119:548\u201354.","journal-title":"Basic Clin Pharmacol Toxicol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02682-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02682-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02682-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T13:16:55Z","timestamp":1747747015000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02682-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2682"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02682-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"1 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Ethical Committee of Lanzhou University Second Hospital according to the Declaration of Helsinki. All animal experiments were conducted in accordance with the Guidelines for endpoints in animal study proposals. All the procedures used in these experiments were approved by the Ethics Committee of Lanzhou University Second Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"826"}}